Larazotide Acetate (AT-1001) Dosage & Reconstitution Protocol
Larazotide Acetate (GGVLVQPG) Zonulin Antagonist Octapeptide
A synthetic 8-amino-acid tight-junction regulator (GGVLVQPG) that acts as a direct antagonist of zonulin to prevent intestinal barrier disassembly ("leaky gut") and antigen paracellular translocation.
- Typical Dose
- 250–500 mcg
- Frequency
- 2-3x daily before meals
- Cycle Length
- 4–12 weeks
- Administration
- oral
Larazotide Acetate (AT-1001) Reference VialSynergistic Protocols
Popular Larazotide Acetate (AT-1001) Stacks & Co-Administration
The Wolverine Stack (BPC-157 + TB-500)
Accelerates tendon, ligament, muscle, and joint recovery by pairing localized angiogenesis (BPC-157) with systemic actin upregulation (TB-500).
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| BPC-157 | 250–500 mcg daily (10–20 U on 5mg/2mL) | Once or split AM/PM SubQ |
| TB-500 (Thymosin Beta-4) | 2.0–2.5 mg twice weekly (or 350–500 mcg daily) | SubQ abdominal or near injury |
Stacking Note: Can be drawn into the same insulin syringe immediately prior to injection or purchased as a pre-mixed 10mg/10mg blend vial.
The GLOW Protocol (GHK-Cu + BPC-157 + TB-500)
Combines high-dose copper peptide (50 mg GHK-Cu) with 10 mg BPC-157 and 10 mg TB-500 to remodel collagen, elastin, skin density, and connective tissue while minimizing copper injection sting.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| GHK-Cu (Copper Peptide) | 1.75–2.5 mg per daily draw | Once daily SubQ (3 mL BAC in 70 mg vial) |
| BPC-157 | 350–500 mcg per daily draw | Co-administered in blend |
| TB-500 | 350–500 mcg per daily draw | Co-administered in blend |
Stacking Note: Standard 70 mg GLOW vial reconstituted with 3.0 mL BAC water: drawing 7–10 units delivers ~1.6–2.3 mg GHK-Cu + 330–460 mcg each of BPC-157 and TB-500.
The KLOW Protocol (GHK-Cu + BPC-157 + TB-500 + KPV)
Adds 10 mg KPV (alpha-MSH tripeptide) to the GLOW formula to downregulate NF-kB/TNF-alpha systemic and gastrointestinal inflammation.
| Compound | Protocol Dose | Timing & Route |
|---|---|---|
| GHK-Cu + BPC-157 + TB-500 | 50 mg / 10 mg / 10 mg base | Once daily SubQ (3 mL BAC in 80 mg vial) |
| KPV Tripeptide | 350–500 mcg per daily draw | Co-administered in 80 mg KLOW vial |
Stacking Note: Ideal for protocols targeting simultaneous gut mucosal repair, autoimmune calm, and dermal/tendon remodeling.
Pharmacology & Evidence
Mechanism & Clinical Research
How It Works
Blocks zonulin receptor binding on intestinal epithelial cells, preventing myosin light-chain kinase (MLCK)-mediated cytoskeletal rearrangement and preserving ZO-1 and occludin tight junctions.
Common Dosing References
oral
250-500mcg · 2-3x daily before meals
4-12 weeks
subcutaneous
250-500mcg · Once daily
4-8 weeks
Research use only. Not medical advice.
What The Research Shows
- 2023
Larazotide Acetate (AT-1001) receptor pharmacology and dosing investigation
Demonstrated dose-dependent biological activity and target pathway engagement in published research studies
Regulatory Status
Research compound; not FDA-approved for general clinical use unless otherwise noted. Verify third-party COA purity and consult a licensed physician.
Clinical Profile
Potential Benefits
- Targeted receptor activation in preclinical and clinical research models
- Standardized vial-based reconstitution and U-100 insulin syringe dosing
- Investigated for tissue support, metabolic signaling, or cellular longevity
Reported Side Effects
- Injection site redness or mild irritation
- Transient headache or fatigue
- Mild gastrointestinal discomfort at higher doses
Provider Directory
Confirmed Clinics & Sourcing
Sourcing Notes
Supplied as lyophilized powder in sterile multi-dose vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) and verify batch purity via HPLC and mass spectrometry COA.
Free Guide
Get Larazotide Acetate (AT-1001) research updates
New studies, regulatory changes and sourcing notes on the peptides you follow. One email a week, no spam.
Free. No spam. Unsubscribe anytime. From GLP1Search.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.